



March 12, 2015

Vericel to Host Fourth-Quarter 2014 Earnings Call on March 23, 2015

CAMBRIDGE, Mass., March 12, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following conference call and webcast:

What: Vericel, Inc., Fourth Quarter 2014 Earnings Call

When: Monday, March 23, 2015 at 4:30pm (EDT)

Where: <http://investors.vcel.com/events.cfm>

How: -- The conference call will be available live in the Investors section of the Vericel website at <http://investors.vcel.com/events.cfm>. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary.

-- To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation fourth quarter 2014 investor conference call.

If calling from outside the U.S., please use the international phone number (253) 237-1173.

If you are unable to participate during the live call, the webcast will be available at <http://investors.vcel.com/events.cfm> until March 23, 2016. A replay of the call will also be available until 11:59 pm (EDT) on March 27, 2015 by calling (855) 859-2056, or from outside the U.S. at (404) 537-3406. The conference ID is 84844964.

About Vericel Corporation

Vericel Corporation (formerly Aastrom Biosciences, Inc.) is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. Vericel is also developing MACI™, a third generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at www.vcel.com.

CONTACT: Chad Rubin

The Trout Group

crubin@troutgroup.com

(646) 378-2947

Or

Lee Stern

The Trout Group

lstern@troutgroup.com

(646) 378-2922